LB Pharmaceuticals Statistics
Total Valuation
LBRX has a market cap or net worth of $1.26 billion. The enterprise value is $941.66 million.
| Market Cap | 1.26B |
| Enterprise Value | 941.66M |
Important Dates
The next estimated earnings date is Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LBRX has 32.26 million shares outstanding. The number of shares has increased by 8,821.45% in one year.
| Current Share Class | 32.26M |
| Shares Outstanding | 32.26M |
| Shares Change (YoY) | +8,821.45% |
| Shares Change (QoQ) | +6.71% |
| Owned by Insiders (%) | 0.73% |
| Owned by Institutions (%) | 83.14% |
| Float | 26.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.38 |
| P/TBV Ratio | 3.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.08, with a Debt / Equity ratio of 0.02.
| Current Ratio | 15.08 |
| Quick Ratio | 13.91 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.00% and return on invested capital (ROIC) is -32.48%.
| Return on Equity (ROE) | -50.00% |
| Return on Assets (ROA) | -29.98% |
| Return on Invested Capital (ROIC) | -32.48% |
| Return on Capital Employed (ROCE) | -27.02% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, LBRX has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +144.63% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +144.63% |
| 50-Day Moving Average | 43.17 |
| 200-Day Moving Average | 30.31 |
| Relative Strength Index (RSI) | 32.35 |
| Average Volume (20 Days) | 293,917 |
Short Selling Information
The latest short interest is 5.28 million, so 16.36% of the outstanding shares have been sold short.
| Short Interest | 5.28M |
| Short Previous Month | 5.16M |
| Short % of Shares Out | 16.36% |
| Short % of Float | 19.95% |
| Short Ratio (days to cover) | 15.39 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -91.38M |
| Pretax Income | -85.68M |
| Net Income | -85.69M |
| EBITDA | -91.03M |
| EBIT | -91.38M |
| Earnings Per Share (EPS) | -$3.81 |
Balance Sheet
The company has $327.79 million in cash and $5.22 million in debt, with a net cash position of $322.57 million or $10.00 per share.
| Cash & Cash Equivalents | 327.79M |
| Total Debt | 5.22M |
| Net Cash | 322.57M |
| Net Cash Per Share | $10.00 |
| Equity (Book Value) | 332.35M |
| Book Value Per Share | 11.59 |
| Working Capital | 331.74M |
Cash Flow
In the last 12 months, operating cash flow was -$82.40 million and capital expenditures -$435,000, giving a free cash flow of -$82.83 million.
| Operating Cash Flow | -82.40M |
| Capital Expenditures | -435,000 |
| Depreciation & Amortization | 345,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -82.83M |
| FCF Per Share | -$2.57 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8,821.45% |
| Shareholder Yield | -8,821.45% |
| Earnings Yield | -6.78% |
| FCF Yield | -6.55% |
Analyst Forecast
The average price target for LBRX is $53.38, which is 36.21% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $53.38 |
| Price Target Difference | 36.21% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |